Metastatic Breast Cancer Update From 2019 SABCS - Metastatic Breast Cancer Trial Talk

Conference Talk

At the 2019 San Antonio Breast Cancer Symposium, researchers reported findings from clinical trials that could lead to new treatment options for some patients with metastatic breast cancer. These studies included:

• HER2CLIMB: This phase III study looked at the combination of the experimental drug tucatinib, trastuzumab (Herceptin®) and capecitabine (Xeloda®) in HER2-positive MBC patients previously treated with Herceptin, pertuzumab (Perjeta®), and T-DM1 (Kadcyla®). The study showed the new regimen extended survival outcomes longer than Herceptin® and Xeloda® alone, including in patients with brain metastases.

• SOPHIA: Updated data from the phase III SOPHIA trial, which compared margetuximab and chemotherapy to trastuzumab (Herceptin®) and chemotherapy in patients with HER2-positive metastatic breast cancer previously treated with other HER2-targeted drugs showed margetuximab improved progression-free survival.

• DESTINY: This phase II clinical trial looked at the investigational drug trastuzumab deruxtecan (T-DXd; DS-8201) in patients with advanced HER2-positive breast cancer who had already tried many other treatments. It showed a response rate of almost 61%.

Below you can learn more about these studies as well as other findings that are important to the MBC community.

HER2CLIMB Trial — Tucatinib

SOPHIA Trial — Margetuximab

Destiny Trial — Trastuzumab Deruxtecan (DS-8201a; T-DXd)

PEARL Trial — endocrine therapy with palbociclib

Oral Chemotherapy

Other Trials (slide presentations)

2019 SABCS Coverage by

2019 SABCS Coverage by Living Beyond Breast Cancer (LBBC)

SABCS and Patient Advocacy

Last Modified on February 10, 2021



for past articles or specific information.